<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392779</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1601-16-01</org_study_id>
    <nct_id>NCT03392779</nct_id>
  </id_info>
  <brief_title>Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating&#xD;
      single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of&#xD;
      ZSP1601 on an empty stomach (fasted condition) and following a high fat, high calorie meal&#xD;
      (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts&#xD;
      (Ascending single dose, multiple dose and food effect). Participants will receive either&#xD;
      ZSP1601 or placebo .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind phase 1 trial including 3 parts: single ascending&#xD;
      dose(SAD) part,multiple ascending dose(MAD) part and postprandial pharmacokinetics part.The&#xD;
      primary aims of the study as below:&#xD;
&#xD;
      Evaluating the safety and tolerance of single and multiple dose of ZSP1601 in healthy&#xD;
      volunteers.&#xD;
&#xD;
      Evaluating the fasting and postprandial pharmacokinetic parameters of ZSP1601 in healthy&#xD;
      volunteers.&#xD;
&#xD;
      Eligible participants will be admitted to the trial center on Day -1. Subjects will be&#xD;
      randomly assigned to either experimental groups or placebo groups, according to a&#xD;
      randomisation schedule in a (4:1) ratio (8 in per experimental group). Subjects in SAD will&#xD;
      receive 25、50、100、175、275、350 mg once daily respectively.Each dose will be administrated&#xD;
      after assurance of safety for the former dose. Subjects in MAD will receive 50 or 100 mg once&#xD;
      daily for 14days respectively.The treatment in food effect consists of 2 periods,and subjects&#xD;
      will receive 100mg on fasting and postprandial states respectively. There will be a 7-day&#xD;
      wash out period between treatment periods.To monitor AEs,record abnormalities (12-lead&#xD;
      ECG,Vital signs,Physical examination,Clinical Laboratory),and detect the pharmacokinetics of&#xD;
      ZSP1601.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Actual">March 22, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking for Participant, Investigator and Clinical Research Associate</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses(single,multiple and food effect)of ZSP1601 and placebo.</measure>
    <time_frame>SAD Group: Up to 4 days, MAD: Up to 17days, FE group: Up to 11 days after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant Medication</measure>
    <time_frame>UP to 4, 17, 11 days for SAD, MAD, FE part respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Abnormalities(Blood routine test, serum biochemical test, conventional coagulation examinations, urine examination ) post dose of ZSP1601 and placebo.</measure>
    <time_frame>UP to 4, 17, 11 days for SAD, MAD, FE part respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG Abnormalities following oral dosing of ZSP1601 and placebo.</measure>
    <time_frame>UP to 4, 17, 11 days for SAD, MAD, FE part respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs Abnormalities following oral dosing of ZSP1601 and placebo.</measure>
    <time_frame>UP to 4, 17, 11 days for SAD, MAD, FE part respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination Abnormalities following oral dossing of ZSP1601 and placebo.</measure>
    <time_frame>UP to 4, 17, 11 days for SAD, MAD, FE part respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac color ultrasound(UCG) Abnormalities following multiple oral doses of ZSP1601 and placebo.</measure>
    <time_frame>Screening, Day17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast（AUC0-t）of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf（AUC0-∞）of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>Tmax is defined as the time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2z of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>t1/2z is defined as the time to decline half of the drug concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose PK Parameter: Ae of ZSP1601</measure>
    <time_frame>Up to Day 2 post-dose</time_frame>
    <description>Ae is defined as the amount of unchanged drug excreted in urine or faeces after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose PK Parameter: Fe0-t of ZSP1601</measure>
    <time_frame>Up to Day 2 post-dose</time_frame>
    <description>Fe0-t is defined as the cumulative excretion rate of the drug in urine and feces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr of ZSP1601</measure>
    <time_frame>UP to 2, 16, 9 days for SAD, MAD, FE part respectively</time_frame>
    <description>CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose plasma PK parameter: Rac of ZSP1601 at steady state</measure>
    <time_frame>Up to 16days</time_frame>
    <description>Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose plasma PK parameter: DF of ZSP1601 at steady state</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>DF is defined as the percentage of fluctuation in steady state is 100 * (Cmax, ss - Cmin, ss)/Cavg, ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose plasma PK parameter: Cmin of ZSP1601 at steady state</measure>
    <time_frame>Up to 16days</time_frame>
    <description>Cmin is defined as the minimum observed concentration of drug in plasma at steady state.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-25 mg while fasted(Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 25 mg /Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-50 mg while fasted(Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 50 mg/Placebo&#xD;
Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-100 mg while fasted(Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 100 mg/Placebo&#xD;
Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-175 mg while fasted(Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 175 mg/Placebo&#xD;
Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 275 mg/Placebo&#xD;
Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(single dose)-350 mg while fasted(Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601 350 mg/Placebo&#xD;
Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(food effect)-100 mg (Cohort FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.&#xD;
Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(multiple doses)-50 mg (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE&#xD;
ZSP1601 50 mg/Placebo for 14 Days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601(multiple doses)-100 mg (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.&#xD;
ZSP1601 100 mg/Placebo for 14 Days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 25 mg</intervention_name>
    <description>ZSP1601 tablet administered orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-25 mg while fasted(Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 25mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-25 mg while fasted(Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 50 mg</intervention_name>
    <description>ZSP1601 tablet administered orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-50 mg while fasted(Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 50 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-50 mg while fasted(Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 100 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily in the fasting state</description>
    <arm_group_label>ZSP1601(single dose)-100 mg while fasted(Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 100 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state</description>
    <arm_group_label>ZSP1601(single dose)-100 mg while fasted(Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 175 mg</intervention_name>
    <description>ZSP1601 tablets administerekd orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-175 mg while fasted(Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 175 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-175 mg while fasted(Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 275 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily in the fasting state</description>
    <arm_group_label>ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 275 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state</description>
    <arm_group_label>ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 350 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-350 mg while fasted(Cohort 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 350mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition</description>
    <arm_group_label>ZSP1601(single dose)-350 mg while fasted(Cohort 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 100 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily under fasted or fed condition</description>
    <arm_group_label>ZSP1601(food effect)-100 mg (Cohort FE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 100mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition</description>
    <arm_group_label>ZSP1601(food effect)-100 mg (Cohort FE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 50 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).</description>
    <arm_group_label>ZSP1601(multiple doses)-50 mg (Cohort 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 50 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).</description>
    <arm_group_label>ZSP1601(multiple doses)-50 mg (Cohort 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 100 mg</intervention_name>
    <description>ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).</description>
    <arm_group_label>ZSP1601(multiple doses)-100 mg (Cohort 8)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 100 mg</intervention_name>
    <description>Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).</description>
    <arm_group_label>ZSP1601(multiple doses)-100 mg (Cohort 8)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are required to meet the following criteria in order to be included in the&#xD;
             trial:&#xD;
&#xD;
               1. Signature of a dated Informed Consent Form (ICF) indicating that the subject has&#xD;
                  been informed of all the relevant aspects(including adverse events) of the trial&#xD;
                  prior to enrollment.&#xD;
&#xD;
               2. Subjects must be willing and able to adhere to the visit schedule and protocol&#xD;
                  requirements and be available to complete the study.&#xD;
&#xD;
               3. Subjects(including partners)have no gestation plans and must use reliable methods&#xD;
                  of contraception during the study and until 6 months following the last dose of&#xD;
                  investigational product.&#xD;
&#xD;
               4. Males and female subjects between 18-50 years (Both inclusive).&#xD;
&#xD;
               5. Body weight is no less than 50kg in males and no less than 45kg in females.Body&#xD;
                  mass index (BMI) 18≤BMI≤28 kg/m2; BMI is determined by the following equation:&#xD;
                  BMI = weight/height2 (kg/m2).&#xD;
&#xD;
               6. Physical condition:No significant abnormalities in medical history, including&#xD;
                  cardiovascular system, liver, kidneys, gastrointestinal system, neural system,&#xD;
                  respiratory system (eg.asthma,asthma induced by exercise,chronic obstructive&#xD;
                  pulmonary disease), mental, metabolism, etc.&#xD;
&#xD;
               7. Subjects in general good health or No significant abnormalities in the opinion of&#xD;
                  the investigator as determined by vital signs and a physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. The average daily smoking are more than 5 cigarettes within 3 months prior to&#xD;
                  screening.&#xD;
&#xD;
               2. Known hypersensitivity and/or allergy to some drugs and food.&#xD;
&#xD;
               3. Known history of drug or alcohol abuse.(defined as consumption of 14 units of&#xD;
                  alcohol per week:1 unit=285ml of beer; or the equivalent of 25ml of spirit, or&#xD;
                  100ml of wine )&#xD;
&#xD;
               4. Subjects who donated blood or bleeding profusely(&gt; 400 mL)in the 3 months&#xD;
                  preceding study screening.&#xD;
&#xD;
               5. Dysphagia or any medical history in gastrointestinal that interferes with the&#xD;
                  absorption of drugs.&#xD;
&#xD;
               6. History or presence of any disease or condition known to increase the risk of&#xD;
                  bleeding, eg.acute gastritis, duodenal ulcer, etc.&#xD;
&#xD;
               7. Frequently suffers from postural hypotension.&#xD;
&#xD;
               8. History of frequent nausea or vomit causes by any etiology.&#xD;
&#xD;
               9. Concomitant therapy with any drugs with known hepatic enzyme-inducing or&#xD;
                  inhibiting agents that may change the activity of CYP3A4 prior to screening or&#xD;
                  during the study.&#xD;
&#xD;
              10. Use of any prescription or over-the-counter (OTC) medications, vitamins and&#xD;
                  herbal or dietary supplements within 14 days prior to screening.&#xD;
&#xD;
              11. History of having any special food(including dragon&#xD;
                  fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere&#xD;
                  with the absorption, distribution, metabolism, or excretion of drug within 14&#xD;
                  days prior to screening.&#xD;
&#xD;
              12. Subjects with recent significant change in diet or exercise .&#xD;
&#xD;
              13. Participated in another clinical research study and received any investigational&#xD;
                  products within 3 months prior to dosing.&#xD;
&#xD;
              14. Inability to consume the food provided in the study ( a high fat, high calorie&#xD;
                  meal includes two eggs for 100g, bacon 20g, a butter toast for 50g, french fries&#xD;
                  for 115g, whole milk for 240ml).This requirement only applies to subjects under&#xD;
                  fed condition.&#xD;
&#xD;
              15. Presence of clinically significant abnormalities in ECG or QTc&gt;470ms in males,or&#xD;
                  QTc&gt;480ms in females.&#xD;
&#xD;
              16. Pregnancy or breastfeeding at screening and during the study.All female subjects&#xD;
                  of childbearing potential must have a negative urine pregnancy test at screening&#xD;
                  and during the trial.&#xD;
&#xD;
              17. Any clinically significant abnormality upon physical examination or in the&#xD;
                  clinical laboratory tests. History or presence of a clinically significant&#xD;
                  gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic,&#xD;
                  pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s)&#xD;
                  (but not limited to above disorders).&#xD;
&#xD;
              18. Presence of human immunodeficiency virus (HIV), viral hepatitis(including&#xD;
                  hepatitis C virus (HCV) or hepatitis B virus (HBV) ),treponema pallidum&#xD;
                  antibodies at screening.&#xD;
&#xD;
              19. Any acute illness or concomitant medication from screening to first dosing.&#xD;
&#xD;
              20. Have chocolate, any food or beverage that contains caffeine or xanthine within 24&#xD;
                  hours prior to dosing.&#xD;
&#xD;
              21. Take any product contains alcohol within 24 hours prior to dosing.&#xD;
&#xD;
              22. Positive for urine drug screening or history of substance abuse for a period of 5&#xD;
                  consecutive years before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

